Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J A Stafford

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Journal of American College Health : J of ACH|March 1, 1995
Comments on the asthma protocolH D Jones, J A Stafford
The New Zealand Medical Journal|September 27, 1978
Patient self-sufficiency: re-organisation of a diabetes clinicD W Beaven, A Helm, J A Stafford, et al.
American Heart Journal|June 30, 2001
Post-myocardial infarction risk stratification in elderly patientsK P Alexander, A N Galanos, J G Jollis, et al.
Annals of Neurology|April 1, 1984
Alzheimer's disease: a study of epidemiological aspectsA Heyman, W E Wilkinson, J A Stafford, et al.
Archives of Disease in Childhood|December 1, 1989
Type II hyperprolinaemia in a pedigree of Irish travellers (nomads)M P Flynn, M C Martin, P T Moore, et al.
Circulation|June 3, 1997
Relationship between physician and hospital coronary angioplasty volume and outcome in elderly patientsJ G Jollis, E D Peterson, C L Nelson, et al.
Biochemistry|June 6, 1998
Dual inhibition of human type 4 phosphodiesterase isostates by (R, R)-(+/-)-methyl 3-acetyl-4-[3-(cyclopentyloxy)-4-methoxyphenyl]-3- methyl-1-pyrrolidinecarboxylateG Tian, W J Rocque, J S Wiseman, et al.
Journal of Medicinal Chemistry|November 24, 1995
Design and synthesis of conformationally constrained analogues of 4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one (Ro 20-1724) as potent inhibitors of cAMP-specific phosphodiesteraseM F Brackeen, D J Cowan, J A Stafford, et al.
Journal of Medicinal Chemistry|December 22, 1995
Introduction of a conformational switching element on a pyrrolidine ring. Synthesis and evaluation of (R*,R*)-(+/-)-methyl 3-acetyl-4-[3- (cyclopentyloxy)-4-methoxyphenyl]-3-methyl-1-pyrrolidinecarboxylate, a potent and selective inhibitor of cAMP-specific phosphodiesteraseJ A Stafford, J M Veal, P L Feldman, et al.
Journal of Medicinal Chemistry|April 28, 1995
Phosphodiesterase type IV inhibition. Structure-activity relationships of 1,3-disubstituted pyrrolidinesP L Feldman, M F Brackeen, D J Cowan, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Journal of American College Health : J of ACH|March 1, 1995
Comments on the asthma protocolH D Jones, J A Stafford
The New Zealand Medical Journal|September 27, 1978
Patient self-sufficiency: re-organisation of a diabetes clinicD W Beaven, A Helm, J A Stafford, et al.
American Heart Journal|June 30, 2001
Post-myocardial infarction risk stratification in elderly patientsK P Alexander, A N Galanos, J G Jollis, et al.
Annals of Neurology|April 1, 1984
Alzheimer's disease: a study of epidemiological aspectsA Heyman, W E Wilkinson, J A Stafford, et al.
Archives of Disease in Childhood|December 1, 1989
Type II hyperprolinaemia in a pedigree of Irish travellers (nomads)M P Flynn, M C Martin, P T Moore, et al.
Circulation|June 3, 1997
Relationship between physician and hospital coronary angioplasty volume and outcome in elderly patientsJ G Jollis, E D Peterson, C L Nelson, et al.
Biochemistry|June 6, 1998
Dual inhibition of human type 4 phosphodiesterase isostates by (R, R)-(+/-)-methyl 3-acetyl-4-[3-(cyclopentyloxy)-4-methoxyphenyl]-3- methyl-1-pyrrolidinecarboxylateG Tian, W J Rocque, J S Wiseman, et al.
Journal of Medicinal Chemistry|November 24, 1995
Design and synthesis of conformationally constrained analogues of 4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one (Ro 20-1724) as potent inhibitors of cAMP-specific phosphodiesteraseM F Brackeen, D J Cowan, J A Stafford, et al.
Journal of Medicinal Chemistry|December 22, 1995
Introduction of a conformational switching element on a pyrrolidine ring. Synthesis and evaluation of (R*,R*)-(+/-)-methyl 3-acetyl-4-[3- (cyclopentyloxy)-4-methoxyphenyl]-3-methyl-1-pyrrolidinecarboxylate, a potent and selective inhibitor of cAMP-specific phosphodiesteraseJ A Stafford, J M Veal, P L Feldman, et al.
Journal of Medicinal Chemistry|April 28, 1995
Phosphodiesterase type IV inhibition. Structure-activity relationships of 1,3-disubstituted pyrrolidinesP L Feldman, M F Brackeen, D J Cowan, et al.
Pageof 2